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Abstract Several reports have indicated that the chemo-
kine receptor CCR5 and its ligands, especially CCL5 (for-
merly known as RANTES), may play a role in the
pathogenesis of psoriasis. The purpose of this investigation
was to examine the expression of CCR5 and its ligands in
chronic plaque psoriasis and to evaluate the clinical and
immunohistochemical eVect of a CCR5 receptor inhibitor.
Immunohistochemical analysis showed low but signiWcant
increased total numbers of CCR5 positive cells in epider-
mis and dermis of lesional skin in comparison to non-
lesional skin. However, relative expression of CCR5 pro-
portional to the cells observed revealed that the diVerence
between lesional and non-lesional skin was only statisti-
cally signiWcant in the epidermis for CD3 positive cells and
in the dermis for CD68 positive cells. QuantiWcation of
mRNA by reverse transcriptase-polymerase chain reaction
only showed an increased expression of CCL5 (RANTES)
in lesional skin. A randomized placebo-controlled clinical
trial in 32 psoriasis patients revealed no signiWcant clinical
eVect and no changes at the immunohistochemical level
comparing patients treated with placebo or a CCR5 inhibi-
tor SCH351125. We conclude that although CCR5 expres-
sion is increased in psoriatic lesions, this receptor does not
play a crucial role in the pathogenesis of psoriasis.
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Introduction
Psoriasis is a chronic skin disease aVecting approximately
2–3% of the population worldwide. Despite its common
occurrence, the exact pathogenesis of psoriasis remains
unclear and adaptations to the pathogenesis of this inXam-
matory disease are continuing [4,  9,  31,  35,  40,  52].
Although the speciWc eVector cells responsible for the
inXammatory process in psoriasis are not known, reported
beneWcial eVects of speciWc T cell targeted therapies, such
as cyclosporine A, DAB389IL-2 and alefacept support a
central role for T cells in the pathogenesis of psoriasis [3, 5,
10, 13, 15, 24, 25]. Further investigation on the immuno-
phenotype and cytokine secretion patterns of T cells have
indicated that speciWcally Th1-cells are involved in psoria-
sis [2, 32, 46].
In the many aspects encompassing T-cell homeostasis,
the traYcking of T cells from blood to tissues is thought to
be relevant in chronic inXammatory diseases such as psori-
asis. Key factors in this migration are chemo-attractant
cytokine molecules known as chemokines and their recep-
tors [30, 33, 37, 38, 57, 61, 62]. The predominant chemo-
kine receptors expressed on Th1-cells are CCR5 and
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CXCR3 [7, 9, 29, 30, 33, 34, 47, 50]. Besides its preferen-
tial expression on Th1 cells, CCR5 is also expressed on
monocytes, macrophages, natural killer and dendritic cells:
all thought to be signiWcant elements in the pathogenesis of
psoriasis [8, 11, 12, 18, 26, 27, 36, 39, 41, 43, 54].
The ligands of CCR5 [CCL3, CCL4 and CCL5 (for-
merly known as MIP1, MIP1 and RANTES, respec-
tively)] are highly expressed by keratinocytes in psoriatic
tissue [19, 22, 42, 48]. Furthermore, it has been demon-
strated that the proinXammatory cytokines IFN- and TNF-
 can induce the expression of these chemokines [19, 22]
and that treatment of psoriasis resulted in a signiWcant
decrease of CCL5, as well as a reduction of CCR5+ T cells
in the skin [19, 20, 58].
Several animal models resembling psoriasis have been
developed, yet, none of these models imitates psoriasis
completely, hence limiting their utility [51]. Investigations
by Mack et al. [36] showed a diVerent expression pattern of
CCR5 in mice and humans. Additionally, diVerent expres-
sion of a single amino acid in the CCR5 molecule between
rhesus macaques and humans resulted in a diVerent
response to inhibitors of the receptor in the species [6].
Therefore, research on the expression of CCR5 in psoriasis,
as well as clinical eYcacy of a CCR5 inhibitor, is limited to
humans. So far, the data available on the expression of
CCR5 in psoriatic skin in humans are not univocal (varying
from high to minimal) and were obtained with divergent
methods in investigations in which CCR5 was never the
main focus [20, 27, 49, 58, 59].
The primary purpose of this study was to determine the
expression of CCR5 and its ligands in chronic plaque psori-
asis in situ compared to non-lesional skin, through analysis
by immunohistochemistry and quantitative reverse trans-
criptase-polymerase chain reaction (RT-PCR). In order to
examine the possibility that CCR5 plays a functional role in
the pathogenesis of psoriasis, we also analyzed clinical and
immunohistochemical data obtained from lesional and non-
lesional skin biopsies of psoriasis patients before and after
treatment with a CCR5 inhibitor.
Materials and methods
Study design and patients
Lesional and non-lesional skin biopsies were obtained from
nine patients with moderate to severe chronic plaque psoria-
sis, deWned by the psoriasis area severity index (PASI) ¸ 8.
These skin biopsies were analyzed by manual quantiWcation
of immunohistochemical double-staining and quantitative
RT-PCR. In order to get insight in the possibility of a func-
tional role of CCR5 in the pathogenesis of psoriasis, 34
patients, including the previous 9 patients, participated in an
8 week, randomized, placebo-controlled, parallel group,
multi-centre, double-blind clinical trial in which patients
received either 50 mg twice daily of the CCR5 inhibitor
SCH351125 (23 patients) or matched placebo (11 patients)
orally for 28 days, followed by a follow-up period of
4 weeks. During the follow-up period patients were only
allowed to use emollients as treatment and on day 56 vital
signs, PASI and blood were assessed. Patients were included
at the dermatology outpatient departments of four academic
hospitals from April 2004 to December 2004. At baseline
and the last day of treatment (day 28), lesional biopsies were
taken to evaluate the immunohistochemical eVect of the
CCR5 inhibitor. For this immunohistochemical evaluation,
single-stained sections were analyzed with digital image
analysis, semi-quantitative analysis (SQA) and confocal
scanning microscopy, and double-stained sections on base-
line and day 28 were analyzed by manual quantiWcation. To
evaluate the clinical eVect of the CCR5 inhibitor the PASI
was assessed at baseline, day 28 and day 56.
In all patients,  psoriasis was diagnosed at least
12 months prior to enrolment and patients were not allowed
to use systemic psoriasis treatment or phototherapy within
4 weeks of study entry. Only emollients were allowed as
topical treatment. All other topical anti-psoriasis therapy
(e.g. corticosteroids, vitamin D derivates, etc.) had to be
stopped 2 weeks before study entry. The protocol was
reviewed and approved by the medical ethical committees
of all participating centres and all patients gave their writ-
ten informed consent before enrolment. The study was con-
ducted according to the Declaration of Helsinki principles
and is registered at the ISRCT register (http://www.con-
trolled-trials.com/ISCRT14986467).
Biopsies
Four-millimeter biopsies were taken from the inside border
of a target psoriatic plaque, preferentially from a non-sun-
exposed area. Lesional biopsies from each patient were
obtained from the same target lesion, separated by at least
1 cm. The biopsy samples were randomly coded, snap-fro-
zen in Tissue-Tek OCT compound (Sakura Finetek Europe,
Zoeterwoude, The Netherlands) by immersion in liquid
nitrogen and stored at ¡80°C until processing. Five-micro-
meter cryostat sections were cut and mounted on glass slides
(Star Frost adhesive slides, Knittelgläser, Braunschweig,
Germany), before being stored at ¡80°C until immunohisto-
chemical staining. For each staining three sections of each
biopsy were analyzed to minimize random variation.
Immunohistochemistry
After  Wxation of the slides, the endogenous peroxide
activity was inhibited with 0.1% sodium azide and 0.3%Arch Dermatol Res (2007) 299:305–313 307
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hydrogen peroxide in Tris-buVered saline (TBS), before
incubating for 15 min with 10% normal goat serum in
TBS. Next, the sections were incubated for 1 h at room
temperature (overnight at 4°C in the case of CCR5) with
the primary antibody in 1% bovine serum albumin (BSA;
Sigma-Chemical Co, St. Louis, MO, USA) in TBS. The
following mouse anti-human monoclonal antibodies were
used: FITC-conjugated anti-CD3 (BD Pharmingen, San
Jose, CA, USA), FITC-conjugated-anti CD68 (clone
EBM11; Dako), anti-human neutrophil elastase (Dako,
Glostrup, Denmark), anti-cytokeratin 8.12 (keratin 16;
Sigma, Saint Louis, MO, USA), anti-CD161 (NK-T cells;
BD Pharmingen) and anti-CCR5 (CD195; BD Pharmin-
gen). After rinsing with TBS, sections were further incu-
bated with biotin-conjugated goat anti-mouse antibody
(Dako) or, in case of CD3 and CD68 staining, with rabbit
anti-FITC (Dako) in 10% normal human serum (NHS) in
TBS for 30 min. Following a wash step with TBS, sec-
tions were subsequently incubated with horseradish per-
oxidase (HPR)-conjugated streptavidin (Dako) or, in case
of CD3 staining, with HRP-conjugated goat anti-rabbit
antibody (Dako), in 1% BSA in TBS for 30 min. In case
of CCR5 staining an ampliWcation step was performed
with the TSA biotin system (Perkin Elmer, Boston, MA,
USA). Sections were counterstained with Mayer’s hae-
matoxylin (Merck, Darmstadt, Germany) and mounted in
Kaiser’s glycerol gelatine (Merck). Skin sections were
double stained with anti-CCR5 together with anti-CD3 or
macrophage marker anti-CD68. The double stained sec-
tions were manually counted by two independent observ-
ers blinded for order, patient and clinical data. Using a
0.5 £ 0.5 mm ocular grid and at 200£ magniWcation, sin-
gle red (CCR5+), single blue (CD3+ or CD68+), and pur-
ple double-positive cells were counted in the entire
section. The epidermal and dermal regions were sepa-
rately counted. The results are expressed as the number of
double-positive cells/mm2.
RNA analysis
RNA was extracted from frozen skin biopsies using the
RNeasy mini kit (Qiagen). RNA quantity was assessed by
OD at 260 nm and RNA quality was analyzed by measur-
ing the ratio of 28s and 18s rRNA using the Agilent 2100
bioanalyzer.
Quantitative PCR
Taqman primers and probes were designed with Primer
Express software (ABI), and purchased from ABI. The
sequences of the human primers and probes are available
upon request. For the human skin tissue, quantitative
PCR was carried out with an ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). The PCR reactions were prepared using
the components from the Invitrogen Platinum Quantita-
tive RT-PCR One-Step kit and assembled according to
the manufacturer’s instructions (Invitrogen, Carlsbad,
CA, USA). The Wnal concentrations of the primers and
probe in the PCR reactions were 200 and 100 nM,
respectively. The RT-PCR reactions for each gene were
performed in a single 384-well plate. Separate plates of
the same RNAs were used to quantitate 18S RNA as an
internal control for RNA quality, and a primer/probe set
for the CD4 promotor was used to check the RNAs for
genomic contamination. The PCR data was quantitated
based on a standard curve generated using fourfold serial
dilutions of the target genes. The fourfold dilutions
began at 0.25 ng, and eight dilutions were used to gener-
ate the standard curve. This procedure provides an abso-
lute quantitation of the amount of CCR5 mRNA in a
given tissue. Data were analyzed using Sequence Detec-
tion Systems software version 1.7 (Applied Biosystems,
Foster City, CA, USA).
Digital image analysis
Single stained sections were randomly coded and analyzed
by computer-assisted image analysis as described previ-
ously in detail [23]. In short, images were acquired and ana-
lyzed using Syndia algorithm on a Qwin based analysis
system (Leica, Cambridge, UK). Twenty high power Welds
per section were analyzed. Positive staining of cellular
markers was expressed as positive cells/mm2.
Semi-quantitative analysis
For keratinocyte expression of K16 keratin, a semi-quan-
titative score was done by two independent observers,
blinded for order, patient and clinical data, with a standard
binocular light microscope (Olympus) at 200£ magniWca-
tion. The semi-quantitative score ranged from 0 to 4+. A
score of 0 represented no expression, while a score of 4
represented abundant expression in all layers of the
epidermis.
Confocal scanning microscope
Cryosections of 5 m on silanized slides were Wxed with
acetone and dried at room temperature, and stored at
¡80°C. Sections were incubated in PBS-3% BSA for
30 min and washed with PBS before all steps. Next, mono-
clonal anti-human CCR-5 antibody (R&D Systems,
MAB183, clone 45549.11), Texas red immunoglobulins
diluted in PBS-3% BSA (1:100) was applied, followed by
application of the primary monoclonal speciWc antibodies308 Arch Dermatol Res (2007) 299:305–313
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CD3 (clone SK7; BD Biosciences), CD4 (clone SK3; BD
Biosciences), CD8 (clone DK25, DakoCytomation) or
CD68 (clone KP1, DakoCytomation). Next, FITC-conju-
gated aYnipure rabbit anti-mouse IgG (Jackson, A =4 9 2 ,
E = 520) diluted in PSB-3% BSA (1:200) was applied and
sections were mounted in Xuorescent mounting medium
(DakoCytomation). Of each double stained slide three pic-
tures were taken with an image deWnition of 1024/1024 pix-
els at a magniWcation of 25£.
Sample size calculation
The randomized placebo controlled clinical trial was tar-
geted to randomize a total of 30 subjects (20 on active treat-
ment and 10 on placebo). With this sample size, the trials
would be able to detect a diVerence of 38% in the response
rate from the placebo group assuming a 0% response rate in
the placebo group with 80% power at an alpha level of 0.05
(two-sided test).
Randomization
Randomization was stratiWed by sites. Each site was
assigned a Wxed number of subjects numbers; e.g. site 1
would get numbers 1–9 and so on. Once the physician of
the study site would enroll a subject, the subject would
be assigned the next available subject number assigned
to the site, starting with the bottom of the list; e.g. the
Wrst subject enrolled in site 1 would get number 1, the
second subject would get number 2, and so on. Treat-
ments would be assigned in an active to placebo ratio of
2:1 according to a computer generated randomization
schedule. No stratiWcation based on age, sex or other
characteristics was performed. Throughout the study
both patient and treating physician were blinded to the
group assignment.
Statistical analysis
We used SPSS 12.0.1 for Windows (SPSS, Chicago, IL,
USA) for the statistical analysis of clinical data. The
Mann–Whitney test was used to compare lesional and
non-lesional skin at baseline and to compare skin biop-
sies before and after treatment. All statistical tests were
two-sided: P values less than 0.05 were considered sig-
niWcant. The results are expressed as median § standard
error of the mean. To evaluate the clinical eVect of treat-
ment with a CCR5 inhibitor, an intention to treat analysis
was performed. Quantitative PCR data analysis was
performed by two-sided t test as implemented by Graph-
pad Prizm (version 4.0 Graphpad Software, San Diego,
CA, USA). A P value less than 0.05 was considered
signiWcant.
Results
Comparison of CCR5 expression in lesional 
versus non-lesional psoriatic skin
The expression of CCR5 in T cells (CD3) and macrophages
(CD68) in lesional and non-lesional skin of nine psoriasis
patients was compared at baseline. We observed a clear
expression of CCR5 which was primarily present in the
dermis. In absolute numbers approximately half of the T
cells and half of the macrophages co-expressed CCR5
(Fig. 1). The CD3+CCR5+ and CD68+CCR5+ double posi-
tive cells showed a low but statistically signiWcant
increased expression of CCR5 in epidermis and dermis of
lesional skin in comparison to non-lesional skin, as shown
in Fig. 1. Focussing on the expression of CCR5 as the per-
centage of all T cells or macrophages present in the sec-
tions, the diVerence between lesional and non-lesional skin
was only statistically signiWcant in the epidermis for CD3+
cells (P < 0.05) and in the dermis for CD68+ cells
(P < 0,001).
Quantitative RT-PCR analysis indicated no increased
expression of mRNA for CCR5 and CCR5-ligand CCL4
(MIP-1) in lesional skin (Fig. 2), only the expression of
CCR5-ligand CCL5 (RANTES) and IL-8 was signiWcantly
increased in lesional skin (P < 0.0001 and P <0 . 0 5 ) .  T h e
well-known enhanced expression of IL-8 in psoriatic skin
was included as positive control.
Lack of clinical eYcacy of SCH351125: a CCR5 inhibitor
In total 34 patients were randomized, as shown in Fig. 3.
The demographical data of the patients are shown in
Table 1. With regards to co-morbidities, one patient had
hypercholesterolemia and one had obesity in the placebo
group. In the SCH351125 group one patient also had
obesity and two had a history of hypertension. After treat-
ment with the CCR5 inhibitor there was no change in
mean PASI in the SCH351125 group (n = 23) [15.5 § 3.8
at baseline, 15.4 § 7.4 at day 28 (Fig. 4a)]. Three of the
patients treated with SCH351125 (13%) attained an
improvement of 50% or more compared to baseline (PASI
50 responders), showing improvements of 67, 77 and
69%. In the placebo group (n = 9) the mean PASI slightly
decreased (14.2 § 4.7 at baseline, 12.9 § 3.7 at day 28).
None of the patients treated with placebo showed an
improvement of more than 50%. All changes observed
were not statistically signiWcant. In the follow-up period
no changes in mean PASI were seen in either treatment
groups.
In the treatment group four patients discontinued. One
patient developed an erythrodermic eruption after 4 days of
treatment, which was considered by the site physician as aArch Dermatol Res (2007) 299:305–313 309
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Fig. 1 Immunohistochemical 
analysis of CCR5 in lesional ver-
sus non-lesional skin. Data are 
shown as mean § SD; ns non-
signiWcant, * P <0 . 0 5 ,  
** P < 0.01, *** P <0 . 0 0 1
Fig. 2 mRNA analysis of 
CCR5 in lesional psoriatic skin 
in comparison with non-lesional 
skin. IL-8 is used as a control 
marker. * P < 0.0001, 
** P <0 . 0 5310 Arch Dermatol Res (2007) 299:305–313
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serious adverse event (SAE). Two patients discontinued
due to adverse events (AEs): one developed shingles in the
n.trigeminus area of the right side of his face after 8 days of
treatment and one patient discontinued due to hair loss after
21 days of treatment. One patient discontinued due to non-
compliance. In the placebo group two patients discontinued
due to AEs: both exacerbation of their psoriasis after
2 weeks of treatment.
CCR5 expression before and after treatment 
with SCH351125
Immunohistochemical analysis of lesional tissue samples
from the SCH351125 group and the placebo group revealed
no statistically diVerent expression of CCR5 between base-
line and day 28 in both treatment groups, as illustrated by
Fig. 4b, c. When focusing on the markers CD3, CD68,
CD161, elastase and K16 in relation to the clinical
response, no statistically signiWcant diVerence after 28 days
of treatment with either SCH351125 or placebo was found
(Fig. 4d), except for elastase and dermal CCR5+CD3+ cells,
which were statistically signiWcantly lowered in the three
PASI 50 responders treated with SCH351125. Additional
data obtained by confocal scanning microscopy corre-
sponded with the digital image and SQA (data not shown).
Discussion
The primary objective of this study was to explore the pos-
sibility of involvement of CCR5 in the pathogenesis of
chronic plaque psoriasis. Therefore we determined the
expression of CCR5 in situ at the protein and mRNA level
by immunohistochemical analysis and, quantitative RT-
PCR, respectively. The total number of single positive
(CCR5+) and double positive (CCR5+CD3+ and
CCR5+CD68+) cells in lesional psoriatic skin signiWcantly
outnumbered those in non-lesional skin. However, when
expressed as percentage of CD3 or CD68 cells, the diVer-
ence between lesional versus non-lesional expression was
less clear. With the latter approach we found that the pro-
portion of CCR5 expression was signiWcantly higher in the
epidermal CD3+ cells and dermal CD68+ cells only, when
comparing lesional skin to non-lesional skin.
Analysis of CCR5 mRNA expression demonstrated a
slight, though not signiWcant, increased expression of
CCR5 in lesional psoriatic skin, perhaps due to the small
numbers of patients. In line with earlier observations we
found that the mRNA expression for RANTES [19, 48] and
IL-8 [1, 17, 21, 45, 53] was signiWcantly higher expressed
in the lesional samples. However, in contrast to previous
research [42] the expression of MIP1 was not increased in
lesional psoriatic skin.
In summary, our results do not provide a clear answer to
our objective of determining whether the percentage of
CCR5 expressing cells is similar in lesional and non-
lesional skin, or if this percentage is increased in lesional
skin.
To assess any possible functional participation of CCR5
in the development or maintenance of psoriatic plaques we
investigated the clinical response to treatment with a CCR5
inhibitor as well as the eVect of this drug on the inXamed
skin in situ. The randomized placebo-controlled clinical
trial revealed no signiWcant clinical eVect and changes at
the immunohistochemical level between patients treated
with placebo or the CCR5 inhibitor. The speciWc type and
dose of the CCR5 inhibitor used in this clinical trial has
proven its eYcacy previously in vitro, in vivo and clinical
studies with other diseases in which CCR5 is known to play
a pivotal or signiWcant role [14, 44, 55, 56, 60]. However,
only three patients treated with the CCR5 inhibitor demon-
strated a clinical improvement of 50% or more. It cannot be
Fig. 3 Flow chart of randomized, placebo controlled clinical trial.
SCH351125 CCR5 ligand inhibitor, SAE serious adverse event, AE ad-
verse event
Table 1 Demographical data patients
a Mean (§SD)
SCH351125 CCR5 ligand inhibitor, PASI psoriasis area and severity
index, BSA body surface area
Randomized clinical trial
Placebo SCH351125
Number 11 23
Male:female 7:4 18:5
Age (years)a 41.8 (10.2) 49.4 (14.3)
Duration of skin disease (years)a 20.6 (9.8) 19.8 (11.6)
Baseline PASIa 14.9 (4.7) 15.7 (4.3)Arch Dermatol Res (2007) 299:305–313 311
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excluded that this low and not statistically signiWcant num-
ber of patients is due to a spontaneous improvement,
reXecting the unpredictability of psoriasis. Surprisingly, the
immunohistochemical markers analyzed in the skin biop-
sies of the so-called PASI 50 responders, did only partially
correspond with the clinical response. Of all immunohisto-
chemical markers only elastase and dermal CCR5+CD3+
showed a signiWcant decline after 28 days of treatment.
Notably, the expression of CD3, a marker known to corre-
spond well with the clinical severity as measured by PASI,
was increased after treatment with SCH351125 in two out
of the three responding patients (Fig. 4d). In addition, their
baseline expression of CD3 was lower in comparison with
the other patients while their PASI was similar. This incon-
sistency could be due to the low number of patients or sug-
gests an individual diVerence in CD3 kinetics.
The increased expression of CCR5 observed by immu-
nohistochemistry and the increased mRNA expression of
CCR5-ligand RANTES in lesional psoriatic skin may
suggest an involvement of this receptor and ligand in psori-
asis. However, our clinical trial with an eVective CCR5
inhibitor unequivocally demonstrated that this is not the
case. Previous research has shown increased expression of
several chemokines and chemokine receptors in psoriasis,
[16, 21, 27, 28, 49] indicating that multiple receptors may
participate in regulating T cell recruitment to the inXamed
skin. Furthermore, RANTES is known to also bind with
CCR1 and CCR3, whereas MIP1 is solely connected to
CCR5. Given this complexity of interactions between
chemokines and chemokine receptors, it is not unlikely that
blocking a single chemokine receptor (i.e. CCR5) would
have been insuYcient in diminishing the inXammatory pro-
cess.
According to Homey [26], chemokine antagonistic
approaches to impede with the inXammatory process may
perhaps be preventive rather than therapeutic. Chemokines
and their receptors play an essential role in the traYcking of
T cells to all kinds of tissue, including the skin. Yet, once
Fig. 4 Clinical and immunohis-
tochemical respons after treat-
ment with a CCR5 receptor 
inhibitor. In a randomized pla-
cebo controlled clinical trial 34 
psoriasis patients were random-
ized for treatment with a CCR5 
receptor inhibitor (SCH351125) 
or placebo for 28 days. Clinical 
eYcacy was measured by psori-
asis area and severity index (PA-
SI) (a). Lesional skin biopsies 
were taken from all patients at 
baseline and day 28 to evaluate 
immunohistochemical eVect. 
Immunohistochemical single 
staining of CCR5 of a patient 
treated with SCH351125 at 
baseline (b) and day 28 (c). 
Immunohistochemical markers 
in relation to clinical response 
(d). PASI 50 non-responder, 
improvement of PASI of less 
than 50%; PASI 50 responder, 
improvement of PASI of 50 or 
more percent; data are shown as 
mean § SD; ns non-signiWcant; 
1P =0 . 0 5312 Arch Dermatol Res (2007) 299:305–313
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leucocytes have entered the target organ and underwent
activation processes, impairment of recruitment of patho-
genic T cells is likely to be less eVective in reducing the
clinical symptoms. When combined with a successful erad-
icative treatment of the T cells, chemokine antagonists
could perhaps be promising candidates for prevention of
acute Xares, prolongation of lesion-free interval and there-
fore provide optimized long-term management of patients
suVering from chronically relapsing inXammatory skin dis-
ease such as psoriasis. So, although CCR5 does not seem to
be a key chemokine receptor in the pathogenesis of psoria-
sis, further eVorts are needed to unravel the complete set of
chemokines and chemokine receptors signiWcant in the
recruitment of inXammatory cells in psoriasis, and may
help to identify crucial molecules, as demonstrated previ-
ously by TNF in various immune mediated inXammatory
diseases.
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